1. Home
  2. PLX vs LARK Comparison

PLX vs LARK Comparison

Compare PLX & LARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLX
  • LARK
  • Stock Information
  • Founded
  • PLX 1993
  • LARK 1885
  • Country
  • PLX Israel
  • LARK United States
  • Employees
  • PLX N/A
  • LARK N/A
  • Industry
  • PLX Biotechnology: Biological Products (No Diagnostic Substances)
  • LARK Major Banks
  • Sector
  • PLX Health Care
  • LARK Finance
  • Exchange
  • PLX Nasdaq
  • LARK Nasdaq
  • Market Cap
  • PLX 160.2M
  • LARK 135.9M
  • IPO Year
  • PLX 1998
  • LARK N/A
  • Fundamental
  • Price
  • PLX $2.59
  • LARK $27.39
  • Analyst Decision
  • PLX Strong Buy
  • LARK
  • Analyst Count
  • PLX 1
  • LARK 0
  • Target Price
  • PLX $15.00
  • LARK N/A
  • AVG Volume (30 Days)
  • PLX 764.3K
  • LARK 24.6K
  • Earning Date
  • PLX 03-17-2025
  • LARK 04-30-2025
  • Dividend Yield
  • PLX N/A
  • LARK 3.07%
  • EPS Growth
  • PLX N/A
  • LARK 6.33
  • EPS
  • PLX 0.04
  • LARK 2.26
  • Revenue
  • PLX $53,399,000.00
  • LARK $58,168,000.00
  • Revenue This Year
  • PLX $67.17
  • LARK N/A
  • Revenue Next Year
  • PLX $55.31
  • LARK N/A
  • P/E Ratio
  • PLX $71.07
  • LARK $12.03
  • Revenue Growth
  • PLX N/A
  • LARK 3.55
  • 52 Week Low
  • PLX $0.82
  • LARK $17.05
  • 52 Week High
  • PLX $2.76
  • LARK $28.55
  • Technical
  • Relative Strength Index (RSI)
  • PLX 58.97
  • LARK 67.52
  • Support Level
  • PLX $2.43
  • LARK $26.13
  • Resistance Level
  • PLX $2.62
  • LARK $27.50
  • Average True Range (ATR)
  • PLX 0.14
  • LARK 1.05
  • MACD
  • PLX 0.02
  • LARK 0.12
  • Stochastic Oscillator
  • PLX 85.00
  • LARK 74.51

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The bank is principally engaged in the business of attracting deposits from the general public and using such deposits, together with borrowings and other funds, to originate one-to-four-family residential real estate, construction and land, commercial real estate, commercial, agriculture, municipal and consumer loans. In addition, it also invests in certain investment and mortgage related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.

Share on Social Networks: